2011年16家增長(zhǎng)最快的明星公司
Celgene生物制藥公司
Celgene生物制藥公司 排名:第57位 連續(xù)在榜年數(shù):3年 ????這家生物制藥公司去年進(jìn)行了兩筆重大并購(gòu)——買下了制藥公司Gloucester和生物技術(shù)公司Abraxis——以推進(jìn)其成為腫瘤治療領(lǐng)域領(lǐng)導(dǎo)者的目標(biāo)。在國(guó)際擴(kuò)張、銷售增長(zhǎng)和近期并購(gòu)等因素助力下,該公司今年銷售收入增長(zhǎng)9.359億美元,達(dá)到36億美元。 ????2009年,藥物薩力多胺(Thalidomide,一種安眠藥,鎮(zhèn)靜劑——譯注)大獲成功,Celgene公司首度登上本榜單,排在第22位。該藥此前曾因會(huì)引起先天畸型而遭禁,但此后即改變用途,成為多發(fā)性骨髓瘤的特效藥。現(xiàn)在,公司可以靠雷利米得(Revlimid)和阿扎胞苷(Vidaza,治療血液和骨髓疾病)來(lái)獲得銷售收入的持續(xù)增長(zhǎng)。 |
Celgene 100 Fastest-Growing Rank: 57 Consecutive years on the list: 3 ????The biopharmaceutical company made two major acquisitions last year -- the pharmaceutical company Gloucester and biotech firm Abraxis -- to advance its goal of becoming an oncology leader. Revenues this year grew by $935.9 million to hit $3.6 billion, aided by the company's international expansion, sales growth, and its newly acquired companies. ????Celgene made its debut on Fortune's Fastest-Growing Companies list in 2009 at No. 22, riding on the success of its drug Thalidomide, which was previously shunned for causing birth defects but was repurposed as a treatment for multiple myeloma. It now can credit drugs Revlimid and Vidaza (for blood and bone marrow conditions) for its continued growth in revenues. |